GSK plc has raised hopes of an improved treatment option for tuberculosis (TB), the world's biggest infectious disease killer over the last decade, after posting promising mid-stage data on a first-in-class investigational antitubercular agent.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?